Cognition Therapeutics share price logo

Cognition Therapeutics

NASDAQ: CGTX

$0.69

+0.00

(+0.44%)

Live

as on

Cognition Therapeutics Stock Performance

as on November 10, 2026 at 6:35 am IST

  • Day's Low

    Day's High

    $0.68
    $0.73
    downward going graph

    1.45%

    Downside

    5.80%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $0.55
    $1.83
    downward going graph

    20.28%

    Downside

    164.49%

    Upside

    downward going graph

Cognition Therapeutics share price movements today

Previous Close
$0.69
Open
$0.69
Volume
425.3K
Market Cap
$65.3M
Day's Low - High
$0.68 - $0.73
52 Week Low - High
$0.55 - $1.83

Cognition Therapeutics Historical Returns

1 Month Return
-21.66 %
3 Month Return
-36.39 %
1 Year Return
-58.61 %
3 Year Return
-31.3 %
5 Year Return
-94.71 %

Cognition Therapeutics Stock Fundamentals & Key Indicators

Check Cognition Therapeutics market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$65.3M

EPS (TTM)

-0.1688

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-4.07

Industry PE ratio

-3.15

PEG Ratio

-0.03

EBITDA

-15.8M

Revenue (TTM)

-

Profit Margin

0.00%

Return On Equity TTM

-50.57%

Cognition Therapeutics vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Cognition Therapeutics with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
Buy$65.3M-94.71%-4.070.00%0.00%
Neutral$101.5B7.32%-35.9528.00%0.00%
StrongBuy$46.5BNA66.6588.39%0.00%
StrongBuy$138.7B186.30%34.9485.57%0.00%
Buy$93.5B46.74%19.2685.77%0.41%

Stock Returns calculator for Cognition Therapeutics Stock including INR - Dollar returns

The Cognition Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

Cognition Therapeutics investment value today

Current value as on today

₹44,012

Returns

-₹55,988

(-55.99%)

Returns from Cognition Therapeutics Stock

-₹58,434 (-58.43%)

Dollar Impact

₹2,446 (+2.45%)

Analyst Recommendation on Cognition Therapeutics Stock

Based on 9 analysts

BUY

88.89%

Buy

11.11%

Hold

0.00%

Sell

Based on 9 analysts, 88.89% of analysts recommend a 'BUY' rating for Cognition Therapeutics. Average target price of $3.33

Cognition Therapeutics Share Price Target

Get share price movements and forecasts by analysts on Cognition Therapeutics.

What analysts predicted

79.28%UPSIDE

Target Price

$3.33

Current Price

$0.69

Analyzed by

9 Analysts

Target

$3.33

Cognition Therapeutics target price $3.33, a slight upside of 79.28% compared to current price of $0.69. According to 9 analysts rating.

Indian Investors' Interest in Cognition Therapeutics Stock

Search interest for Cognition Therapeutics Stock has decreased by -21% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-21% versus previous 30 day period

Cognition Therapeutics Quarterly Profit & Loss

All numbers in Millions USD

Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Total Revenue
-
-
-
-
-
-
-
-
-
-
Gross Profit
0
-
-
-
-
0
-
0
-
-
Operating Income
-14
-14
-10
-13
-13
-6
-13
-8
-7
-7
EBITDA
-6
-9
-7
-8
-6
-4
-3
-4
-3
-4
Interest Expense
0
0
0
0
0
-
0
0
0
0
Depreciation
0
0
0
0
0
0
0
0
0
0
Income Before Tax
-7
-9
-7
-8
-6
-4
-3
-4
-3
-4
Income Tax Expense
-
-
-
-
-
-
-
-
-
-
Net Income
-7
-9
-7
-8
-6
-4
-3
-4
-3
-4
Net Profit Margin
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%

Cognition Therapeutics Annual Profit & Loss

All numbers in Millions USD

Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
-
-
-
-
-
-
-
Gross Profit
0
0
-
0
-
-
-
Operating Income
-17
-17
-28
-43
-50
-53
-47
EBITDA
-3
-5
-10
-21
-25
-33
-23
Interest Expense
1
1
0
0
0
0
0
Depreciation
0
0
0
0
0
0
0
Income Before Tax
-4
-7
-11
-21
-25
-33
-23
Income Tax Expense
-
-
-
-22
-
-
-
Net Income
-6
-10
-11
0
-25
-33
-23
Net Profit Margin
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%

Cognition Therapeutics Quarterly Cash Flow

All numbers in Millions USD

Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Net Income
-7
-9
-7
-8
-6
-4
-3
-4
-3
-4
Operating Cash Flow
-5
-6
-8
-9
-5
-5
-3
-5
-3
-3
Investing Cash Flow
0
-
0
-
-
-
0
-
0
0
Financing Cash Flow
0
0
11
1
0
33
0
0
6
0
Change in Cash
-6
-6
2
-8
-4
28
-2
-5
3
-3

Cognition Therapeutics Annual Cash Flow

All numbers in Millions USD

Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-4
-7
-11
-21
-25
-33
-23
Operating Cash Flow
-3
-3
-3
-18
-16
-28
-24
Investing Cash Flow
0
0
0
0
0
0
0
Financing Cash Flow
2
5
53
5
4
23
36
Change in Cash
0
2
49
-13
-11
-4
11

Global Institutional Holdings in Cognition Therapeutics

Check out the Institutions with significant holdings in Cognition Therapeutics.

Funds
Holdings
Aaron G.L. Fletcher
6.39%
Vanguard
3.54%
VANGUARD INDEX FUNDS
3.49%
Lisa Ricciardi
1.85%
BlackRock, Inc.
1.33%

Cognition Therapeutics News & Key Events

  • img

    Today's Timeline - 05 November

    Thu, 05:09 PM

    -

    Cognition Therapeutics reports Q3 results, net loss of $4.1 million, and FDA alignment on zervimesine study.

Insights on Cognition Therapeutics

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Moderna, Inc. Common Stock has given 265.7% return, outperforming this stock by 297.0%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Moderna, Inc. Common Stock has given 935.8% return, outperforming this stock by 994.4%

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 3 months, CGTX stock has moved down by -36.4%

About Cognition Therapeutics

Cognition Therapeutics, Inc. is a biopharmaceutical company in the clinical stage, focused on identifying and advancing small molecule treatments. The firm's research and development efforts are primarily directed towards age-related neurodegenerative conditions affecting the central nervous system, as well as retinal disorders. Its most advanced experimental therapy is CT1812, which acts as a sigma-2 receptor antagonist. This compound is currently being evaluated in Phase II clinical trials for the management of mild-to-moderate Alzheimer's disease and dementia with Lewy bodies (DLB). Additionally, it has successfully concluded Phase I trials for early-stage Alzheimer's and is undergoing preclinical investigation for dry age-related macular degeneration (AMD). The company's pipeline also includes CT2168, a treatment candidate for synucleinopathies—a category of diseases encompassing DLB and Parkinson's disease—and CT2074, which is in development for dry AMD. Cognition Therapeutics, Inc. was established in 2007 and operates from its headquarters in Purchase, New York.
OrganisationCognition Therapeutics
Headquarters2500 Westchester Avenue, Purchase, NY, 10577, US
IndustryBiotechnology
CEOLisa Ricciardi

Key Management of Cognition Therapeutics

Name

Title

Ms. Lisa Ricciardi

CEO, President & Director

Mr. John Brendan Doyle

Chief Financial Officer

Dr. Anthony O. Caggiano M.D., Ph.D.

Chief Medical Officer

Dr. Steven A. Weissman Ph.D.

VP & Head of CMC

Ms. Anita Cornet

Head of Quality

Mr. Bobby Horn

Corporate Controller

FAQs

What is Cognition Therapeutics share price today?

Cognition Therapeutics share price today is $0.69 as on . Cognition Therapeutics share today touched a day high of $0.73 and a low of $0.68.

What is the 52 week high and 52 week low for Cognition Therapeutics share?

Cognition Therapeutics share touched a 52 week high of $1.83 on and a 52 week low of $0.55 on . Cognition Therapeutics stock price today i.e. is trending at $0.69,which is 62.19% down from its 52 week high and 25.43% up from its 52 week low.

What is Cognition Therapeutics's market capitalisation today?

Cognition Therapeutics market capitalisation is $0.00T as on .

How to invest in Cognition Therapeutics Stock (CGTX) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Cognition Therapeutics on INDmoney app. Click on Buy button.

What is the minimum amount required to buy Cognition Therapeutics Stock (CGTX) from India?

Indian investors can start investing in Cognition Therapeutics (CGTX) shares with as little as ₹93.92749786376953 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹939.27 in Cognition Therapeutics stock (as per the Rupee-Dollar exchange rate as on ). Based on Cognition Therapeutics share’s latest price of $0.69 as on November 10, 2026 at 1:05 am IST, you will get 14.4928 shares of Cognition Therapeutics. Learn more about fractional shares .

What are the returns that Cognition Therapeutics has given to Indian investors in the last 5 years?

Cognition Therapeutics stock has given -94.71% share price returns and 26.61% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?